Cure Ventures
Milenko Cicmil is a highly experienced professional in the field of pharmacology and biomedical research, currently serving as a Visiting Research Fellow at the University of Reading since June 2020. Milenko is also a Partner at Cure Ventures and previously held the position of Chairman of the Board at AMP Discovery from February 2021 to January 2022. With a robust background in leadership roles at Ipsen, FogPharma, and Merck, Milenko has contributed extensively to advancements in external innovation, translational biology, and pharmacology. A former senior researcher at AstraZeneca and GE Healthcare, Milenko's career began with a research fellowship at Cancer Research UK. Educationally, Milenko earned a Bachelor's Degree in Cell/Cellular and Molecular Biology from King's College London and a Ph.D. in Molecular Pharmacology from the University of Reading.
Cure Ventures
Cure Ventures is a venture firm focused on investing in the life sciences and medical technologies. We aim to propel novel cures to market by discovering and enabling biotechnology, pharmaceutical, medical device, and medtech firms with exceptional growth potential committed to addressing unmet medical needs for global patient targets.